MorphoSys AG (MOR) Q3 2022 Earnings Call Transcript

MorphoSys AG (MOR) Q3 2022 Earnings Conference Call November 17, 2022 8:00 AM ET

Company Participants

Julia Neugebauer - Head of Investor Relations
Jean-Paul Kress - Chief Executive Officer
Joe Horvat - US General Manager
Tim Demuth - Chief Research & Development Officer
Sung Lee - Chief Financial Officer

Conference Call Participants

James Quigley - Morgan Stanley
Roy Buchanan - JMP Securities
James Gordon - JPMorgan
Victor Floc'h - Stifel
Suzanne van Voorthuizen - Kempen
Vineet Agrawal - Citi

Operator

Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Third Quarter 2022 Financial Results Conference Call of MorphoSys. Throughout today's recorded call, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. [Operator Instructions]

I would now like to turn the conference over to Julia Neugebauer.

Julia Neugebauer

Ladies and gentlemen, good afternoon and good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys, and its my pleasure to welcome you to our third quarter 2022 financial results conference call.

Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Tim Demuth, Chief Research and Development Officer; and Joe Horvat, US General Manager.

Before we begin, I'd like to remind you on Slide 2 that some of our statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans and expectations for the compounds in our pipeline as well as the development plans of our collaboration partners. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys' 20-F and annual report, all for the year ended December 31, 2021, and from time to time in other